Novel Cancer Vaccination Technology

Engineered Immunotherapy for Cancer

Our mission is to help patients fight cancer

It is the ultimate goal of CyTuVax to provide an innovative solution for the treatment of pancreatic cancer. CyTuVax has developed a revolutionary vaccination technology based on depot-attached cytokines that is capable of activating both the humoral and cellular arms of the immune system for a powerful anti-tumor response.
Rene Vleugels
Managing director

Our mission is to develop effective vaccines for which there is a high medical need. CyTuVax uses its adjuvant technology to develop cancer vaccines that aim to eradicate tumors and prolong the life expectancy of cancer patients. CyTuVax's technology is also applied in new vaccines against viral and bacterial diseases that lack adequate treatment. The powerful adjuvant can also improve the quality of existing vaccines and decrease the number of vaccine injections needed to reach desired protection levels.

CyTuVax has developed a breakthrough, widely applicable and effective vaccination platform technology based on depot-attached cytokines as immune stimulator. The CyTuVax vaccines can generate powerful immune responses and are especially designed for cancer immunotherapy. The distinctive feature of our vaccine is a highly improved and prolonged antigen presentation by dendritic cells, which results in a stronger activation of immune cells.

The CyTuVax vaccination technology is a platform technology in several aspects. It can be applied with a wide range of cytokines aggregates as adjuvant and against a wide range of tumors. The vaccine has been successfully tested in preclinical studies with murine model tumors (fibro-sarcoma, melanoma, kidney, colon, mammary carcinoma and B-lymphoma). The effectiveness of the vaccination technology has also been verified in vaccines against viral targets (Hepatitis B) and bacterial targets (Antrax, Diphtheria and Tetanus).

CyTuVax is currently testing its vaccine technology in a clinical Phase 1 study of a vaccine for hepatitis B non-responders, persons that do not respond to standard hepatitis B vaccines. This clinical trial is being conducted with the Maastricht Universitair Medische Centrum (MUMC). More information about this clinical trial can be found at

Latest news

showCyTuVax is currently testing its vaccine technology in a clinical Phase 2 study of a vaccine for hepatitis B non-responders

Where we are

About us

CyTuVax B.V.
Oxfordlaan 55
6229 EV Maastricht
The Netherlands

This email address is being protected from spambots. You need JavaScript enabled to view it.